ScholarLens Back to search
2019•Best Practice & Research Clinical GastroenterologyRequires access

IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?

Christopher Ma, Remo Panaccione, Reena Khanna, Brian G. Feagan, Vipul Jairath

Open publisher page 34 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 34 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ustekinumab, Interleukin 23, Interleukin 12, Medicine, Immunology, Crohn's disease, Monoclonal antibody, Immune system

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease? — Research Paper | ScholarLens